Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Simcere Pharmaceutical Group
Simcere Pharmaceutical Group
Activities:
Ingredients
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Optimising RNA production for faster and cheaper pharmaceutical manufacturing
RNA production can be a lengthy and complex process, but the Ntensify platform could change this by diminishing development times, decreasing production costs and allowing the...
ChargePoint invest in a single-use manufacturing facility to expand product line
The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Owlstone Medical bags $6.5m to optimise infectious disease diagnostic tool
The Bill & Melinda Gates Foundation has funded the bolstering of the Breath Biopsy platform, as well as research into breath biomarkers in tuberculosis (TB) and HIV
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Finance
Merck and Simcere dissolve cardiovascular and metabolic joint venture
An explosion in the online market for drugs in China cited as a key factor in the decision
Simcere Pharmaceutical Group appoints Chief Scientific Officer
Dr Zang Jingwu to lead research and development team
Finance
Chinese drug majors look to the West to build brands
In China, large drug manufacturers are seeking partnerships, mergers and acquisitions with Western companies, writes Asia correspondent A Nair
Buyouts prove popular in China
Chinese pharma companies turning to private capital
Simcere appoints a chief executive
Hongquan Liu takes up the position next month
Research & Development
Bristol-Myers Squibb announces second pact with Simcere
The firms will co-develop BMS-795311, a preclinical small molecule CETO inhibitor
Finance
Merck and Simcere agree joint venture
Will initially offer drugs for cardiovascular and metabolic diseases
Subscribe now